GlassScriptPhysician profile
Brian R Bishop
NPI 1912907940
$4,521.76
in general payments reported to CMS, 2019-2025
33 companies · $737 in 2025
The $737 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $422 · 2021: $296 · 2022: $570 · 2023: $1,150 · 2024: $1,240 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $923.23 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $785.31 | 2021-2025 | Vraylar, Ubrelvy, Synthroid |
| Pfizer INC. | $571.34 | 2022-2025 | |
| Lilly USA, LLC | $291.52 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $214.74 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.62 | 2022-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $180.63 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $149.81 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.15 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $108.13 | 2020-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $96.85 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $95.00 | 2022-2024 | Quviviq |
| Novo Nordisk INC | $87.35 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Kowa Pharmaceuticals America, INC. | $86.64 | 2023-2025 | Zoryve, Seglentis |
| Corcept Therapeutics | $71.34 | 2024-2025 | Korlym |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.65 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $55.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $48.85 | 2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $45.06 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $43.32 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $32.01 | 2024 | |
| Edwards Lifesciences Corporation | $31.98 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $24.86 | 2025 | Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $22.64 | 2021 | |
| Amneal Pharmaceuticals LLC | $22.37 | 2025 | Unithroid |
| Bausch Health US, LLC | $21.47 | 2025 | Aplenzin |
| Ibsa Pharma INC. | $20.90 | 2025 | Flector, Tirosint, Licart |
| Xeris Pharmaceuticals, INC. | $20.30 | 2023 | Gvoke Hypopen |
| Aimmune Therapeutics, INC. | $17.78 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.63 | 2022 | |
| Organogenesis INC. | $16.00 | 2022 | |
| Eisai INC. | $13.38 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.